Get the Stockscreener App
0.3533
2.00%
-0.0072
After Hours:
.37
0.0167
+4.73%
Applied Therapeutics Inc stock is traded at $0.3533, with a volume of 1.77M.
It is down -2.00% in the last 24 hours and down -13.66% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.3605
Open:
$0.361
24h Volume:
1.77M
Relative Volume:
0.80
Market Cap:
$50.02M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.2617
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
-13.81%
1M Performance:
-13.66%
6M Performance:
-82.60%
1Y Performance:
-91.97%
1-Day Range:
$0.3475
$0.38
1-Week Range:
$0.3475
$0.4218
52-Week Range:
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.3533 | 58.05M | 0 | -119.76M | -55.17M | -1.35 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Rating Increased to Sell at Wall Street Zen - MarketBeat
Janus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Price T Rowe Associates Inc. MD Sells 986,108 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
William Blair Brokers Increase Earnings Estimates for APLT - MarketBeat
Vestal Point Capital LP Acquires 10,355,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Stock Rating Upgraded by Wall Street Zen - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Applied Therapeutics Inc (APLT): An Important Analyst Insights - Stocksregister
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug - MSN
Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial - NewsBreak: Local News & Alerts
New top-line data from Phase II/III trial of govorestat in CMT-SORD - The Pharma Letter
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug By Stocktwits - Investing.com India
Applied Therapeutics Presents Full 12-Month Clinical Results and - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripher - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripheral Nerve Society Meeting | APLT Stock News - GuruFocus
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - The Manila Times
Applied Therapeutics Presents Full 12-Month Clinical - GlobeNewswire
Breakthrough in CMT Treatment: New Clinical Data Shows First-Ever Disease Progression Slowing in 24-Month Study - Stock Titan
Here's Why Amazon Is a Brilliant Buy Now (Hint: It's Not E-Commerce) - The Globe and Mail
Massive News for Apple Stock Investors! - The Globe and Mail
Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) PT at $6.10 - Defense World
Applied Therapeutics’ (APLT) “Sector Perform” Rating Reiterated at Royal Bank of Canada - Defense World
APLT: RBC Capital Reiterates Sector Perform Rating, Price Target Maintained | APLT Stock News - GuruFocus
APLT Reports Financial Position and Advances in Govorestat Resea - GuruFocus
Applied Therapeutics Reports First Quarter 2025 Financial Results | APLT Stock News - GuruFocus
Applied Therapeutics, Inc. SEC 10-Q Report - TradingView
Barclays PLC Sells 27,997 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Alyeska Investment Group L.P. Boosts Stock Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Shareholders that Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky about Pending Class ActionAPLT - ACCESS Newswire
Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Investors who lost money on Applied Therapeutics, Inc.(APLT) should contact Levi & Korsinsky about pending Class ActionAPLT - ACCESS Newswire
Shareholders that Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky About Pending Class ActionAPLT - ACCESS Newswire
Applied Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025APLT - ACCESS Newswire
Shareholders That Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky About Pending Class ActionAPLT - ACCESS Newswire
Class Action Filed Against Applied Therapeutics, Inc. (APLT) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Applied Therapeutics Announces Acceptance of Late-Breaking Abstr - GuruFocus
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - The Manila Times
Applied Therapeutics, Inc. (APLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Applied Therapeutics Inc Stock (APLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
| Funtleyder Leslie D. | Chief Financial Officer |
Aug 22 '24 |
Sale |
5.83 |
13,530 |
78,880 |
277,911 |
| Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
| Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
| Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
| Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):